Development of generic low molecular weight heparins: A perspectiveFAREED, Jawed; LEONG, Wendy; HOPPENSTEADT, Debra A et al.Hematology/oncology clinics of North America. 2005, Vol 19, Num 1, pp v-vi, issn 0889-8588, 18 p.Article

Low-molecular-weight heparin and other new antithrombotic drugsSALZMAN, E. W.The New England journal of medicine. 1992, Vol 326, Num 15, pp 1017-1019, issn 0028-4793Article

Low molecular weight heparin in childrenALBISETTI, Manuela; ANDREW, Maureen.European journal of pediatrics. 2002, Vol 161, Num 2, pp 71-77, issn 0340-6199Article

Attention à l'administration itérative d'HBPM au voyageurLECOMPTE, Thomas.Archives des maladies du coeur et des vaisseaux. Pratique. 2005, Num 136, issn 1261-694X, p. 10Article

Low-molecular-weight heparin in pediatric patientsSUTOR, Anton Heinz; CHAN, Anthony K. C; MASSICOTTE, Patricia et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 31-39, issn 0094-6176, 9 p., SUP1Conference Paper

Les héparines de bas poids moléculaire = Low molecular weight heparinsHELLEY, D.La Lettre du pneumologue. 2001, Vol 4, Num 5, pp 191-194, issn 1292-5977Article

Bleeding after low-molecular-weight heparinTHOMAS, D. P; WITTMANN, P. H; WITTMANN, F. W et al.Lancet (British edition). 1992, Vol 339, Num 8801, pp 1119-1120, issn 0140-6736Article

Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysisWEITZ, J. I; KUINT, J; LESLIE, B et al.Thrombosis and haemostasis. 1991, Vol 65, Num 5, pp 541-544, issn 0340-6245Article

The effect of low molecular weight heparin (enoxaparin) on enhanced coagulation induced by crystalloid haemodilutionLLEWELLYN, R. L; JAMES, M. F. M.Anaesthesia. 2010, Vol 65, Num 10, pp 1013-1016, issn 0003-2409, 4 p.Article

The effect of taurolidine on experimental thrombus formationKAPTANOGLU, Levent; KUCUK, Hasan Fehmi; COLAK, Elif et al.European journal of pharmacology. 2008, Vol 578, Num 2-3, pp 238-241, issn 0014-2999, 4 p.Article

Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgeryBAR-YOSEF, Shahar; COZART, Heidi B; PHILLIPS-BUTE, Barbara et al.Canadian journal of anaesthesia. 2007, Vol 54, Num 2, pp 107-113, issn 0832-610X, 7 p.Article

Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparinSIMONS, R; MALLETT, S. V.Anaesthesia. 2007, Vol 62, Num 11, pp 1175-1178, issn 0003-2409, 4 p.Article

Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparinHAINER, James W; SPROGEL, Per; LINDENSTROEM, Ewa et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 3-9, issn 0094-6176, 7 p., SUP1Conference Paper

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties : Implications for the Development of Generic Versions of Low-Molecular-Weight HeparinsJESKE, Walter P; WALENGA, Jeanine M; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 1, pp 74-85, issn 0094-6176, 12 p.Article

Existe-t-il des différences entre les héparines de bas poids moléculaire ?BONEU, Bernard; GUERRERO, Felipe.STV. Sang thrombose vaisseaux. 2006, Vol 18, pp 6-10, issn 0999-7385, 5 p., NSArticle

A rare case of HITTS following prophylactic LMWH therapy in a blunt trauma victimBARNES, Stephen L; BERNARD, Andrew C; KEARNEY, Paul A et al.Injury. 2005, Vol 36, Num 2, pp 347-351, issn 0020-1383, 5 p.Article

Advantages of low molecular weight heparin over standard heparin : facts and fictionVINAZZER, H.Seminars in thrombosis and hemostasis. 1991, Vol 17, Num 4, pp 385-388, issn 0094-6176Article

Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsZAHIR, Hamim; MATSUSHIMA, Nobuko; HALIM, Abdel-Baset et al.Thrombosis and haemostasis. 2012, Vol 108, Num 1, pp 166-175, issn 0340-6245, 10 p.Article

Timing of postpartum enoxaparin administration and severe postpartum hemorrhageFREEDMAN, Rachel A; BAUER, Kenneth A; NEUBERG, Donna S et al.Blood coagulation & fibrinolysis. 2008, Vol 19, Num 1, pp 55-59, issn 0957-5235, 5 p.Article

Aplasia cutis congenita and low molecular weight heparinSHARIF, Saba; HAY, Charles R. M; CLAYTON-SMITH, Jill et al.BJOG (Oxford. Print). 2005, Vol 112, Num 2, pp 256-258, issn 1470-0328, 3 p.Article

Immediate type hypersensitivity after injection of nadroparin (Fraxiparin)BEKKENK, Morcel W; VAN ZUUREN, Esther J.Thrombosis and haemostasis. 2005, Vol 94, Num 3, pp 673-674, issn 0340-6245, 2 p.Article

Heparin-induced thrombocytopenia in neurologic patients treated with low- molecular-weight heparinPOHL, C; KREDTECK, A; BASTIANS, B et al.Neurology. 2005, Vol 64, Num 7, pp 1285-1287, issn 0028-3878, 3 p.Article

Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in ratsYANG, Tianzhi; MUSTAFA, Fatima; AHSAN, Fakhrul et al.Journal of pharmacy and pharmacology. 2004, Vol 56, Num 1, pp 53-60, issn 0022-3573, 8 p.Article

Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitroOSIP, Stephanie L; BUTCHER, Martin; YOUNG, Edward et al.Thrombosis and haemostasis. 2004, Vol 92, Num 4, pp 803-810, issn 0340-6245, 8 p.Article

A marriage of enhancement: fibrinolysis and conjunctive therapy : Pharmacotherapy in cardiovascular diseases and vascular interventionsC.WELSH, Robert; ARMSTRONG, Paul W.Thrombosis and haemostasis. 2004, Vol 92, Num 6, pp 1194-1200, issn 0340-6245, 7 p.Article